These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11114411)

  • 1. Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes.
    Shiffman ML; Verbeke SB; Kimball PM
    Antiviral Res; 2000 Nov; 48(2):91-9. PubMed ID: 11114411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
    Wang T; Blatt LM; Seiwert SD
    J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
    Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B.
    Ren FY; Jin H; Piao XX; Piao FS
    World J Gastroenterol; 2007 Nov; 13(41):5440-5. PubMed ID: 17907286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.
    Martín J; Navas S; Quiroga JA; Pardo M; Carreño V
    Cytokine; 1998 Aug; 10(8):635-44. PubMed ID: 9722937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
    Tokumoto Y; Hiasa Y; Uesugi K; Watanabe T; Mashiba T; Abe M; Kumagi T; Ikeda Y; Matsuura B; Onji M
    J Infect Dis; 2012 Apr; 205(7):1121-30. PubMed ID: 22357660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C.
    Marinho RT; Pinto R; Santos ML; Lobos IV; Moura MC
    J Viral Hepat; 2004 May; 11(3):206-16. PubMed ID: 15117322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).
    Pires de Mello CP; Drusano GL; Rodriquez JL; Kaushik A; Brown AN
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29890736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.
    Gallegos KM; Drusano GL; D Argenio DZ; Brown AN
    J Infect Dis; 2016 Oct; 214(8):1192-7. PubMed ID: 27496974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
    Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
    Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vivo and vitro effects of interferon-alpha 2b on functional activity of T-lymphocytes from patients with rheumatoid arthritis].
    Iarilina AA; Nikonova MF; Litvina MM; Balabanova RM; Iarilin AA
    Ter Arkh; 2000; 72(5):9-17. PubMed ID: 11109610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
    Laguno M; Murillas J; Blanco JL; Martínez E; Miquel R; Sánchez-Tapias JM; Bargallo X; García-Criado A; de Lazzari E; Larrousse M; León A; Loncá M; Milinkovic A; Gatell JM; Mallolas J
    AIDS; 2004 Sep; 18(13):F27-36. PubMed ID: 15316335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
    Testoni B; Durantel D; Lebossé F; Fresquet J; Helle F; Negro F; Donato MF; Levrero M; Zoulim F
    Gut; 2016 Apr; 65(4):672-82. PubMed ID: 26082258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C.
    Bergamini A; Bolacchi F; Cepparulo M; Demin F; Uccella I; Bongiovanni B; Ombres D; Angelico F; Liuti A; Hurtova M; Francioso S; Carvelli C; Cerasari G; Angelico M; Rocchi G
    Clin Exp Immunol; 2001 Mar; 123(3):459-64. PubMed ID: 11298134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Infect Chemother; 2012 Oct; 18(5):689-97. PubMed ID: 22450877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    Lee JW; Kim W; Kwon EK; Kim Y; Shin HM; Kim DH; Min CK; Choi JY; Lee WW; Choi MS; Kim BG; Cho NH
    PLoS One; 2017; 12(6):e0179094. PubMed ID: 28614389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
    Moskovitz DN; Manoharan P; Heathcote EJ
    Can J Gastroenterol; 2003 Aug; 17(8):479-82. PubMed ID: 12945008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.